13 Jan No Comments admin Uncategorized

BARDA partners with Mapp Biopharmaceutical, Inc. to develop next generation therapeutic for Botulinum Neurotoxin

BARDA and its partner Mapp Biopharmaceutical Inc. will explore the potential of a new monoclonal antibody (mAb) based therapeutic for Botulinum Neurotoxin (BoNT).

Read more